Dysregulation of miR‐543 in Parkinson's disease: Impact on the neuroprotective gene SIRT1

Parkinson's disease (PD) is a progressive and age‐dependent neurodegenerative disease characterised clinically by a variety of motor symptoms and cognitive impairment. PD was initially considered to be a grey matter disease; however, recently, evidence has emerged that white matter changes in PD precede the neuronal loss seen in the grey matter. The cause of these initial white matter changes is yet to be elucidated. Here, we explored whether dysregulated miRNAs and their target mRNA could provide insight into the underlying mechanisms of early white matter changes in PD.

[1]  R. Wu,et al.  The role of noncoding RNAs in Parkinson’s disease: biomarkers and associations with pathogenic pathways , 2021, Journal of Biomedical Science.

[2]  Xiaochen Bo,et al.  clusterProfiler 4.0: A universal enrichment tool for interpreting omics data , 2021, Innovation.

[3]  W. L. Lim,et al.  MicroRNA Dysregulation in Parkinson’s Disease: A Narrative Review , 2021, Frontiers in Neuroscience.

[4]  Min Li,et al.  Resveratrol in Rodent Models of Parkinson’s Disease: A Systematic Review of Experimental Studies , 2021, Frontiers in Pharmacology.

[5]  M. Wael.,et al.  MicroRNA expression changes in Parkinson's disease (PD) patients' leukocytes prior to and following deep brain stimulation (DBS). , 2021, American journal of neurodegenerative disease.

[6]  Xuan Li,et al.  The Critical Role of SIRT1 in Parkinson’s Disease: Mechanism and Therapeutic Considerations , 2020, Aging and disease.

[7]  H. Berendse,et al.  Neuropathological correlates of parkinsonian disorders in a large Dutch autopsy series , 2020, Acta Neuropathologica Communications.

[8]  Fei Wang,et al.  miRTarBase 2020: updates to the experimentally validated microRNA–target interaction database , 2019, Nucleic Acids Res..

[9]  Yan Liu,et al.  miRNA-384-5p regulates the progression of Parkinson's disease by targeting SIRT1 in mice and SH-SY5Y cells , 2019, International journal of molecular medicine.

[10]  A. R. Anwar,et al.  Alterations in White Matter Network and Microstructural Integrity Differentiate Parkinson’s Disease Patients and Healthy Subjects , 2019, Front. Aging Neurosci..

[11]  F. Tan,et al.  Regulatory Mechanism of miR-543-3p on GLT-1 in a Mouse Model of Parkinson's Disease. , 2019, ACS chemical neuroscience.

[12]  J. D. Mills,et al.  Oxidative stress and inflammation in a spectrum of epileptogenic cortical malformations: molecular insights into their interdependence , 2018, Brain pathology.

[13]  Carsten Sticht,et al.  miRWalk: An online resource for prediction of microRNA binding sites , 2018, PloS one.

[14]  A. Corbett Post-transcriptional regulation of gene expression and human disease. , 2018, Current opinion in cell biology.

[15]  F. Hirth,et al.  Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease , 2018, Front. Neurosci..

[16]  H. Kawano,et al.  Interactions between Sirt1 and MAPKs regulate astrocyte activation induced by brain injury in vitro and in vivo , 2017, Journal of Neuroinflammation.

[17]  L. Pihlstrøm,et al.  [Parkinson's disease and parkinsonism]. , 2017, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[18]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[19]  Gene W Yeo,et al.  Pairing beyond the Seed Supports MicroRNA Targeting Specificity. , 2016, Molecular cell.

[20]  T. Beach,et al.  microRNA Profiles in Parkinson's Disease Prefrontal Cortex , 2016, Front. Aging Neurosci..

[21]  Wei Gao,et al.  miR-543 promotes gastric cancer cell proliferation by targeting SIRT1. , 2016, Biochemical and biophysical research communications.

[22]  Wei Zhao,et al.  Down-regulation of the miR-543 alleviates insulin resistance through targeting the SIRT1. , 2015, Biochemical and biophysical research communications.

[23]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[24]  D. Bartel,et al.  Predicting effective microRNA target sites in mammalian mRNAs , 2015, eLife.

[25]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[26]  V. Álvarez,et al.  MiRNA Profile in the Substantia Nigra of Parkinson’s Disease and Healthy Subjects , 2014, Journal of Molecular Neuroscience.

[27]  Vincenzo Bonifati,et al.  Effect of resveratrol on mitochondrial function: implications in parkin-associated familiar Parkinson's disease. , 2014, Biochimica et biophysica acta.

[28]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[29]  Hui Zhou,et al.  starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq data , 2013, Nucleic Acids Res..

[30]  Ana Kozomara,et al.  miRBase: annotating high confidence microRNAs using deep sequencing data , 2013, Nucleic Acids Res..

[31]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[32]  V. Kim,et al.  Regulation of microRNA biogenesis , 2014, Nature Reviews Molecular Cell Biology.

[33]  Sterling C. Johnson,et al.  White Matter Microstructural Integrity and Executive Function in Parkinson's Disease , 2013, Journal of the International Neuropsychological Society.

[34]  E. Katunina,et al.  [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[35]  Bronwen L. Aken,et al.  GENCODE: The reference human genome annotation for The ENCODE Project , 2012, Genome research.

[36]  D. Dickson Parkinson's disease and parkinsonism: neuropathology. , 2012, Cold Spring Harbor perspectives in medicine.

[37]  J. Kordower,et al.  Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. , 2012, Brain : a journal of neurology.

[38]  G. Pasinetti Role of Personalized Medicine in the Identification and Characterization of Parkinson's Disease in Asymptomatic Subjects. , 2012, Journal of Alzheimer's disease & Parkinsonism.

[39]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[40]  S. Vasudevan Posttranscriptional Upregulation by MicroRNAs , 2012, Wiley interdisciplinary reviews. RNA.

[41]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[42]  L. Guarente,et al.  SIRT1 Protects against α-Synuclein Aggregation by Activating Molecular Chaperones , 2012, The Journal of Neuroscience.

[43]  Hui Zhou,et al.  starBase: a database for exploring microRNA–mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data , 2010, Nucleic Acids Res..

[44]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[45]  Thomas Gasser,et al.  Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria , 2009, The Lancet Neurology.

[46]  Stijn van Dongen,et al.  miRBase: tools for microRNA genomics , 2007, Nucleic Acids Res..

[47]  G. Levy,et al.  The relationship of Parkinson disease with aging. , 2007, Archives of neurology.

[48]  E. Lai,et al.  Non-motor Symptoms of Parkinson's Disease , 2007 .

[49]  A. Chiarugi,et al.  The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. , 2005, Trends in pharmacological sciences.

[50]  A. Moorman,et al.  Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data , 2003, Neuroscience Letters.

[51]  L. Guarente,et al.  Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase , 2000, Nature.